PCM
EPZM

Peregrine Capital Management’s Epizyme, Inc EPZM Stock Holding History

Peregrine Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-450,961
Closed -$6.11M – 330
2018
Q2 		$6.11M Sell
450,961
-26,322
-6% -$410K 0.15% 208
2018
Q1 		$8.47M Sell
477,283
-22,717
-5% -$384K 0.21% 173
2017
Q4 		$6.28M Buy
+500,000
New +$7.27M 0.15% 233

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Peregrine Capital Management's EPZM Position: Q3 2018 in Review

Peregrine Capital Management sold out of Epizyme, Inc (EPZM) in Q3 2018, closing a stake of 450,961 shares — an estimated $6.11M sold.

Peregrine Capital Management first reported a position in EPZM in Q4 2017 and held it in 3 quarters. The position peaked at $8.47M in Q1 2018. 104 funds tracked by Wall St. Rank hold EPZM as of Q3 2018.

  • Peregrine Capital Management reported no remaining Epizyme, Inc position as of Q3 2018 after selling out during the quarter.
  • Peregrine Capital Management sold 450,961 Epizyme, Inc shares in Q3 2018, an estimated $6.11M.
  • Peregrine Capital Management first reported a position in Epizyme, Inc in Q4 2017 and held it in 3 quarters.
  • Peregrine Capital Management's Epizyme, Inc position peaked at $8.47M in Q1 2018.
  • 104 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2018.

Based on Peregrine Capital Management's 13F filing for Q3 2018, filed 18 Oct 2018.